Nivestim(TM), A New Biosimilar Filgrastim, Is Approved In Europe For The Prevention Of Febrile Neutropenia Associated With Chemotherapy

Links shared publicly online about this topic.

  • 1,092
    total visits

Nivestim(TM), A New Biosimilar Filgrastim, Is Approved In Europe For The Prevention Of Febrile Neutropenia Associated With Chemotherapy

medicalnewstoday.com —

Hospira announced that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1). Nivestim

View full resource at medicalnewstoday.com

Tags: Poison, Cancer, Chemotherapy, Neutropenia, Neutropenia Medication, Neupogen

  • Share

Most Recently Shared on June 15, 2010 at 1:05 pm By:

mnt_drugapprov MNT Drug Approvals

Nivestim(TM), A New Biosimilar Filgrastim, Is Approved In Europe For The Prevention Of Febrile Neutropenia Associated ... http://mnt.to/3DRJ

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cancer News MNT Cancer News

Advertisement